Q-omics provides the consensus-scored IL17RE profile across patient tissues and cancer cell-line models. IL17RE expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, IL17RE is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, IL17RE RNA expression shows 15,631 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where IL17RE shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL17RE — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL17RE survival associations across molecular data types. IL17RE RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL17RE RNA expression–survival associations across cancer types. High IL17RE expression shows unfavorable associations in HNSC, BRCA, PAAD and UCEC, but favorable associations in UVM and DLBC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for IL17RE RNA expression.
This table summarizes IL17RE tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for IL17RE. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL17RE shows lower tumor expression in KIRC, KIRP, LUAD, KICH, BRCA and LUSC. The KIRC box plot shows higher IL17RE RNA expression in normal versus tumor tissue (log2 FC = −1.598, t-test p < 0.001).
This table shows molecular features associated with IL17RE in patient tissues and cancer cell lines. In patient samples, IL17RE shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, IL17RE RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
